Macrophage Therapeutics, Inc.

Biotechnology ResearchNew Jersey, United States2-10 Employees

Macrophage Therapeutics (MT) is developing novel targeted anti-inflammatory and immuno-oncology therapeutics based on its proprietary Activated Macrophage targeting platform.

MT is leveraging its unique CD206 receptor-based delivery system to deliver proven therapeutics in a more precise and targeted fashion. With binding affinities 10,000X today’s best antibodies MT’s approach eliminates off-target toxicity and increases the efficacy of proven therapeutic agents. MT’s CD206 targeting platform is already clinically established and being used in an FDA/EMEA approved radiopharmaceutical.

Sign up for free to view info

Email Format Employee directory